NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced that it has completed its previously announced offering of 1,623,377 shares of common stock at a price of $3.08 per share to Fletcher International, Ltd., for gross proceeds of $5 million. Under the agreement, Fletcher also has the option to invest up to an additional $15.25 million through the conversion of preferred stock. The shares were offered under the company’s S-3 shelf registration statement previously filed with the Securities and Exchange Commission (SEC).
